Life Quest Clinical Lab is launching Nepal's first Plasma p-Tau217 / β-Amyloid 1-42 Ratio assay — an advanced blood-based biomarker for Alzheimer's disease evaluation. Coming August 2026.
Advanced Blood-Based Biomarker Testing for Alzheimer's Disease Is Coming to Nepal This August
Kathmandu, Nepal — August 2026: Life Quest Clinical Lab is proud to announce the upcoming launch of Nepal's first Plasma p-Tau217 / β-Amyloid 1-42 Ratio assay, bringing an advanced blood-based biomarker for Alzheimer's disease evaluation to patients and healthcare professionals in Nepal.
The introduction of this test represents an important step forward in the field of neurological diagnostics. Alzheimer's disease is a progressive neurodegenerative disorder that can begin developing years before noticeable symptoms of dementia appear. As the global approach to Alzheimer's diagnosis continues to evolve, blood-based biomarkers are increasingly becoming an important part of the diagnostic pathway.
Why Early Detection of Alzheimer's Disease Matters
Alzheimer's disease does not begin suddenly when memory loss or dementia becomes obvious. Biological changes associated with the disease can occur years before significant clinical symptoms become apparent.
Recognising these changes earlier can be valuable for clinical evaluation and patient management. An appropriate biomarker-based assessment may help clinicians:
- Support the differentiation of Alzheimer's disease from other causes of cognitive impairment and dementia.
- Identify patients who may require further neurological evaluation.
- Support clinical decision-making and treatment planning.
- Provide additional information during the assessment of patients with cognitive symptoms.
- Support monitoring and overall clinical evaluation as the disease progresses.
Early diagnosis can therefore provide patients, families, and healthcare professionals with an opportunity to understand the underlying disease process and plan appropriate care.
From Brain Imaging and Lumbar Puncture to a Simple Blood Sample
Historically, the assessment of Alzheimer's disease pathology has relied significantly on specialised investigations such as PET imaging and cerebrospinal fluid (CSF) analysis through lumbar puncture. While these approaches can provide valuable information, they may also be associated with limitations including cost, invasiveness, accessibility, and availability.
The development of blood-based biomarkers is changing this landscape. A plasma biomarker test requires only a blood sample, offering a considerably simpler and more accessible approach to obtaining information related to Alzheimer's disease pathology.
What Is the p-Tau217 / β-Amyloid 1-42 Ratio?
The newly introduced assay measures two important biomarkers associated with Alzheimer's disease pathology: Phosphorylated Tau 217 (p-Tau217) and β-Amyloid 1-42.
The relationship between these biomarkers is expressed as a p-Tau217 / β-Amyloid 1-42 plasma ratio. The combination of amyloid- and tau-related biomarkers provides complementary information about the biological processes associated with Alzheimer's disease.
According to the technology information provided for the assay, the test is designed to detect both amyloid and tau pathology, providing high diagnostic accuracy with high sensitivity and specificity.
A Major Development in Blood-Based Alzheimer's Testing
In May 2025, the U.S. FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio — described as the first FDA-cleared blood test to aid in the diagnosis of Alzheimer's disease. The assay is designed for adults aged 55 years and older with cognitive impairment and is intended to help reduce dependence on PET imaging while improving access to Alzheimer's disease evaluation.
The arrival of this technology in Nepal represents an important opportunity to make advanced biomarker testing more accessible within the country.
Who May Benefit from This Test?
The test may be particularly relevant for patients undergoing clinical evaluation for cognitive impairment where Alzheimer's disease is being considered. It can provide neurologists and physicians with additional biomarker information that may assist in determining the next steps in the diagnostic pathway.
The assay is specifically intended for adults 55 years and older with cognitive impairment. Patients should discuss the appropriateness of testing with their neurologist or treating physician.
Why This Matters for Nepal
Access to advanced neurological diagnostics can be challenging when specialised investigations require patients to travel, undergo invasive procedures, or access facilities that may not be readily available locally. The introduction of a blood-based Alzheimer's biomarker in Nepal has the potential to make an important part of the diagnostic pathway more accessible.
At Life Quest Clinical Lab, we believe that advances in laboratory medicine should translate into better access to meaningful diagnostic information for patients and healthcare professionals. This launch reflects our continuing commitment to expanding specialised laboratory services and bringing advanced international diagnostic technologies closer to patients in Nepal.
Launching August 2026
The Plasma p-Tau217 / β-Amyloid 1-42 Ratio will be available at Life Quest Clinical Lab from August 2026.
For test availability, sample requirements, reporting information, and clinical consultation, healthcare professionals and patients are encouraged to contact Life Quest Clinical Lab.